Cronos Group Inc. (CRON)
CRON Stock Rises 17% in Three Months: Time to Buy the Dip or Cash Out?
Cronos Group stock climbs 17% in three months on strong revenue growth and margin gains, but rising competition and regulatory risks raise questions about its upside.
Cronos Group Investor Day Highlights Cannabis Growth, Cash Flow and Global Ambitions
Cronos Group NASDAQ: CRON used its first Investor Day to outline its cultivation, genetics, brand and financial strategy, emphasizing its purpose-built greenhouse partnership with Mucci Farms, continued international expansion and a focus on cash flow generation.
Cronos: Invest In Cannabis With 50% Net Cash And GAAP Profitability
Cronos Group Inc. is upgraded to a Buy, driven by a best-in-class balance sheet and improved profitability. CRON boasts $827 million in cash, no debt, and strong international expansion, with adjusted gross margins reaching 46%. Profitability is supported by disciplined cost management and positive GAAP operating profit, distinguishing CRON from Canadian peers.
Are Medical Stocks Lagging Cronos Group (CRON) This Year?
Here is how Cronos Group (CRON) and Curaleaf Holdings, Inc. (CURLF) have performed compared to their sector so far this year.
Surging Earnings Estimates Signal Upside for Cronos (CRON) Stock
Cronos Group (CRON) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Cronos Group Q2 Earnings Call Highlights
Cronos Group NASDAQ: CRON reported record second-quarter net revenue, gross profit and adjusted EBITDA for 2026, supported by growth in Israel, Canada and other international markets, including Germany.
Cronos Group (CRON) Surpasses Q2 Earnings and Revenue Estimates
Cronos Group (CRON) came out with quarterly earnings of $0.03 per share, beating the Zacks Consensus Estimate of $0.01 per share. This compares to a loss of $0.1 per share a year ago.
3 Top Canadian Marijuana Stock Picks To Add Value To Your Portfolio
There is a great divide between big cannabis companies like Trulieve cannabis corp. Tilray Holdings Inc., and it's not with each other. The separation is what smaller mom-and-pop cannabis farmers are going to do as the big fish takes over the market. As legal cannabis grows, so does the competition, and this leads to a bittersweet result. For investors and those who hold shares of said big company, it is usually the one that wins in the long run. Marijuana stock investors are focused on companies that show profitability and a path towards change and innovation.
CRON Strengthens Global Footprint: Is the Cannabis Stock Worth Buying?
Cronos Group posts 40% Q1 revenue growth, gains share in Canada and expands abroad, but fierce cannabis competition keeps investors cautious.
Cronos: Strong Q1 Earnings Driven By International Cannabis Sales
Cronos reported strong Q1 performance with record level revenue. International sales are driving growth and the Canadian markets are showing improvement. The company is set to acquire CanAdelaar in the Netherlands which will increase its international operations and revenue potential.
Cronos Group Q1 Earnings Call Highlights
Cronos Group NASDAQ: CRON reported record first-quarter 2026 net revenue and gross profit, with management pointing to growth in Israel, gains for its Spinach brand in Canada and continued international expansion as key drivers of the quarter.
Cronos Group (CRON) Q1 Earnings Meet Estimates
Cronos Group (CRON) came out with quarterly earnings of $0.01 per share, in line with the Zacks Consensus Estimate . This compares to earnings of $0.02 per share a year ago.
